Atossa Therapeutics Secures New Patent for Endoxifen Formulations
Atossa Therapeutics Celebrates Patent Milestone
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a pioneering biopharmaceutical firm focused on innovative treatments for breast cancer, recently announced a significant achievement: the issuance of U.S. Patent No. 12,281,056. This patent addresses unique and highly pure formulations of (Z)-endoxifen, an important compound in the quest to enhance breast cancer treatment options.
The Details of the New Patent
The newly acquired patent consists of 58 claims encapsulating various formulations of (Z)-endoxifen. These include different levels of purity and stability, as well as methods for using these formulations effectively. This addition to Atossa’s intellectual property not only strengthens its position in the market but also affirms its dedication to advancing breast cancer therapies.
Insights from Leadership
Steven Quay, M.D., Ph.D., President and CEO of Atossa, expressed excitement about this new development. He stated that this patent not only shows the strength of their research team but also emphasizes their commitment to protecting innovations that can truly transform breast cancer treatment.
The Value of (Z)-Endoxifen
(Z)-endoxifen is recognized as one of the most effective Selective Estrogen Receptor Modulators (SERMs) available. It helps in inhibiting estrogen receptors and may cause degradation of these receptors. Studies indicate it could also be beneficial for patients resistant to traditional hormonal therapies. Furthermore, (Z)-endoxifen targets the oncogenic protein PKC?1, giving it unique advantages in cancer treatment.
Addressing the Challenges in Breast Cancer Treatment
Standard treatments for breast cancer often involve significant challenges, particularly regarding side effects and long-term efficacy. Atossa Therapeutics is addressing this by developing a proprietary oral formulation of (Z)-endoxifen intended to bypass the acidic environment of the stomach, which can deactivate its therapeutic benefits. This innovation could lead to enhanced tolerability and effectiveness for those undergoing treatment.
Atossa's Commitment to Innovation
The company has built a comprehensive patent estate that now boasts over 200 patent claims related to (Z)-endoxifen formulations and their clinical applications. This robust strategy not only safeguards their discoveries but also underlines Atossa’s commitment to being at the forefront of targeted cancer therapies.
Clinical Applications of (Z)-Endoxifen
Currently, Atossa is focusing on studying (Z)-endoxifen for various applications in both the treatment and prevention of breast cancer. This includes ongoing research aimed at addressing metastatic breast cancer, showcasing the company’s broad approach to tackling the disease.
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is devoted to revolutionizing breast cancer treatment through cutting-edge science and patient-centric approaches. Their flagship candidate, (Z)-endoxifen, represents a major leap forward in the search for effective therapeutics applicable across the spectrum of breast cancer situations. Atossa’s endeavors aim to create breakthroughs that not only improve patient lives but also deliver substantial returns for shareholders.
Frequently Asked Questions
What recent patent has Atossa Therapeutics obtained?
Atossa Therapeutics has been granted U.S. Patent No. 12,281,056, covering new formulations of (Z)-endoxifen.
What is (Z)-endoxifen used for?
(Z)-endoxifen is a potent Selective Estrogen Receptor Modulator used in treating and potentially preventing breast cancer.
How many claims does the new patent cover?
The new patent includes 58 claims related to the formulations and uses of (Z)-endoxifen.
What is the significance of this patent for Atossa?
This patent enhances Atossa's intellectual property portfolio, supporting their mission to innovate treatments for breast cancer.
Who is the contact person for more information about Atossa?
The contact for inquiries is Michael Parks, VP of Investor and Public Relations, reachable at 484-356-7105 or via email at michael.parks@atossainc.com.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
